Literature DB >> 448089

Activation of human complement by liposomes: a model for membrane activation of the alternative pathway.

C M Cunningham, M Kingzette, R L Richards, C R Alving, T F Lint, H Gewurz.   

Abstract

Liposomal model membranes were found to activate the alternative pathway of human complement. Activation was measured by C3 conversion and component consumption in serum that had been incubated with liposomes. C3 conversion did not require C1 or C2 of the classical pathway, since it was observed in serum from a C1r-deficient patient, serum from a C2-dificient patient, and normal serum in buffer containing EGTA and MgCl2. The incubation of liposomes with C2-deficient serum resulted in consumption of components C3 through C9 with no consumption of C1 or C4 in a profile typical of alternative pathwya activation. The reaction was further shown to require alternative pathway factor D, and to be independent of antibody. Activation of the alterative pathway was dependent on the membrane composition of the liposomes. A positive charge was required for liposomes to produce C3 conversion. Liposomal cholesterol concentration and phospholipid fatty acyl chain length and unsaturation all influenced activation, suggesting the importance of membrane fluidity. Positively charged liposomes containing dimyristoyl phosphatidylcholine and cholesterol required the presence of certain glycolipids for C3 conversion. The activation of the alternative complement pathway by liposomes of defined membrane composition may provide a suitable model for the study of alternative pathway activation by cellular membranes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 448089

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

2.  Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.

Authors:  Christine T N Pham; Lynne M Mitchell; Jennifer L Huang; Christopher M Lubniewski; Otto F Schall; J Kendall Killgore; Dipanjan Pan; Samuel A Wickline; Gregory M Lanza; Dennis E Hourcade
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

3.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Authors:  Geoffrey Gifford; Vivian P Vu; Nirmal K Banda; V Michael Holers; Guankui Wang; Ernest V Groman; Donald Backos; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2019-04-08       Impact factor: 9.776

4.  Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats.

Authors:  H Harashima; T M Huong; T Ishida; Y Manabe; H Matsuo; H Kiwada
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  Activation of the alternative complement pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine.

Authors:  N Okada; T Yasuda; T Tsumita; H Okada
Journal:  Immunology       Date:  1982-01       Impact factor: 7.397

6.  Monoclonal antibody specific for myelin glycoprotein P0: derivation and characterization.

Authors:  M C Franko; C L Koski; C J Gibbs; D E McFarlin; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

7.  Complement activation by respiratory syncytial virus-infected cells.

Authors:  K M Edwards; P N Snyder; P F Wright
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Effect of C-reactive protein on the complement-mediated stimulated of human neutrophils by Streptococcus pneumoniae serotypes 3 and 6.

Authors:  C Mold; K M Edwards; H Gewurz
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

9.  Avidin acylation prevents the complement-dependent lysis of avidin-carrying erythrocytes.

Authors:  V R Muzykantov; M D Smirnov; G P Samokhin
Journal:  Biochem J       Date:  1991-01-15       Impact factor: 3.857

10.  ABCA1 (ATP-Binding Cassette Transporter A1) Mediates ApoA-I (Apolipoprotein A-I) and ApoA-I Mimetic Peptide Mobilization of Extracellular Cholesterol Microdomains Deposited by Macrophages.

Authors:  Xueting Jin; Denis Sviridov; Ying Liu; Boris Vaisman; Lia Addadi; Alan T Remaley; Howard S Kruth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-06       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.